NCT05278052招募中3 期
Standard Maintenance Therapy Versus Local Consolidative Radiation Therapy and Standard Maintenance Therapy in 1-5 Sites of Oligometastatic Non-small Cell Lung Cancer (NSCLC): A Phase III Randomized Controlled Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 190
- 试验地点
- 1
- 主要终点
- Overall survival (OS)
研究概览
简要总结
Standard Maintenance Therapy versus Local Consolidative Radiation Therapy and standard maintenance therapy in 1-5 sites of OligoMetastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial
详细描述
Standard of care maintenance therapy alone (standard arm) versus local consolidative radiation therapy and standard of care maintenance therapy (Experimental arm)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years
- •Patients with ECOG performance status of 0-2
- •Patients with pathologically proven diagnosis of NSCLC
- •Patients with 1-5 sites of metastatic disease not including the primary tumor and regional nodes (less than or equal to 3 metastatic lesions in one organ will be eligible and 4 or more metastatic lesions in one organ will be ineligible)
- •Patients who have received standard duration of systemic therapy (4 - 6 cycles) without progression of the disease
- •Patients suitable for definitive therapy to the primary disease
- •All the Oligometastases lesions should be radiologically visible and suitable for ablative doses of radiation in accordance with the dose fractionation regimens specified in the protocol.
- •Patients who have received ablative radiation therapy or surgery or RFA for metastatic sites at presentation or during systemic therapy will be eligible provided the total number of oligometastatic sites at the time of study entry (treated site included) is less than or equal to five.
- •Patients who have received palliative RT for symptomatic bony metastases or RFA will also be eligible provided the treated site is under control on imaging. If not controlled, could be eligible for study if further ablative doses of radiation can be delivered according to the treating physician.
- •Patients who underwent surgical decompression, or stabilization followed by palliative radiation therapy for bony metastases will be eligible in the study provided the treated site is under control on imaging and patient has less than 5 sites of metastases at the time of study entry.
- •Adequate end organ function CBC/differential obtained within 15 days prior to registration on study, with adequate bone marrow function defined as follows:
- •Absolute neutrophil count (ANC) ≥ 500 cells/mm3;
- •Platelets ≥ 50,000 cells/mm3;
- •Hemoglobin ≥ 8.0 g/dl (Use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable);
- •For females of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to study registration;
- •Patients willing for written informed consent and must be willing to comply with the specified follow up schedule
排除标准
- •Patients with progressive disease after initial standard systemic therapy
- •Patients with oncogene driver mutations
- •Patients with more than 5 sites of oligo metastases
- •Patients with metastatic lesion size of more than 5 cm
- •Patients with more than three metastatic lesion in one organ
- •Patients not suitable for definitive radiation therapy to primary disease
- •Patients not suitable for ablative radiation therapy to metastatic sites
- •Patients with malignant peritoneal disease
- •Patients with malignant pleural effusion
- •Leptomeningeal disease
- •Brain metastases in the brain stem
- •Clinical or radiological evidence of spinal cord compression or metastases within 2 mm of spinal cord on MRI
- •Severe, active co-morbidity defined as follows:
- •Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;
- •Transmural myocardial infarction within the last 6 months;
- •Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration;
- •Patients with prior history of radiation therapy to thorax
- •Patients with previous history of malignancy within last 3 years from the date of diagnosis
研究组 & 干预措施
ARM A: Standard maintenance therapy alone
Active Comparator
Maintenance systemic therapy/ observation
干预措施: Standard maintenance therapy as decided by the treating medical oncologist (Drug)
ARM B: Local consolidative radiation therapy (LCRT)
Experimental
Radiation therapy to all oligometastatic sites including primary loco-regional disease
干预措施: Local consolidative radiation therapy (Radiation)
ARM B: Local consolidative radiation therapy (LCRT)
Experimental
Radiation therapy to all oligometastatic sites including primary loco-regional disease
干预措施: Standard maintenance therapy as decided by the treating medical oncologist (Drug)
结局指标
主要结局
Overall survival (OS)
时间窗: Upto 2 years
Overall survival is defined as the duration between the date of randomization to the date of death due to any cause or the date of last follow-up, whichever is earlier.
次要结局
- New distant metastases(Upto 2 years)
- Progression free survival (PFS )(Upto 2 years)
- Local control rates of treated sites(Upto 2 years)
- Response rates(From randomization every 3 months upto 2 years)
- Radiotherapy related toxicity using CTC v5.0 (radiotherapy related acute and late toxicity)(Upto 2 years)
- Health Related QOL using the EORTC-QLQ-C30 questionnaire(From randomization every 3 months till 2 years)
- Health Related QOL using the EORTC- LC13 questionnaire(From randomization every 3 months till 2 years)
研究者
Anil Tibdewal
Principal Investigator
Tata Memorial Hospital
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Additional Consolidated radiation therapy after chemotherapy in limited metastatic lung cancerCTRI/2020/04/024761Anil Tibdewal
进行中（未招募）
2 期
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung CancerNCT03137771NRG Oncology218
尚未招募
2 期
Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal CancerMetastatic Colorectal CancerRadiotherapyNCT03142282Wuhan Union Hospital, China200
已完成
2 期
Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II TrialStage IV Non-Small Cell Lung CancerNCT02045446University of Texas Southwestern Medical Center29
招募中
2 期
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLCExtensive Stage Lung Small Cell CancerNCT06350162Zhejiang Cancer Hospital100